What is the role of processed EEG monitoring in anaesthesia? Do I use the BIS on my next patient? This question is being debated by industry, regulatory authorities, the public, societies of anaesthetists and perhaps, soon, the lawyers.
The B-Aware trial is by far the most important trial relevant to this debate 1 . The B-Aware trial provided good evidence that BIS can reduce awareness in a population at high risk of awareness. It also collected a wealth of useful information about the nature of awareness, and provided data on important secondary endpoints. In this issue Professor Leslie and others present data gathered during the B-Aware trial which analyses the effect of BIS-guided anaesthesia on recovery times 2 .
In this trial the use of BIS was associated with shorter recovery-a matter of a few minutes after long procedures. Importantly, times were measured to discharge eligibility not actual discharge. The B-Aware trial data provides only a weak argument for using BIS to quicken recovery times. The importance of Professor Leslie's paper is that the reduction in awareness was not bought at the potential expense of delayed recovery due to deeper anaesthesia. Other studies have also shown minimal or modest improvements in recovery times after the use of BIS 3 .
Many see the primary role of BIS as awareness prevention. Apart from the B-Aware trial, only one other study has investigated BIS in this role. This Swedish study demonstrated a low rate of awareness when using the BIS in routine paralysed cases 4 . Lack of any contemporary control arm for comparison limits the level of evidence of this study. How relevant are these studies to your next patient? Is the data relevant when we use other EEG technologies or BIS with a different version of the algorithm? Clinical trials are vexed by the question: how much should I apply the results from a study to my individual patient, who is not the average study population patient? It can be argued that trends of benefit found in high risk groups are likely to be repeated in subgroups or related groups-although to differing degrees 5 . It can also be argued that failure to adhere to trial conditions can qualitatively alter outcomes from benefit to risk. In one recent audit of awareness, BIS was associated with a non-significant increase in awareness 6 . It is most likely this was due to confounding variables; alternatively these findings may suggest that use of BIS is only of benefit when adhering to strict protocol as in the B-Aware trial.
From the time of Galen, predicting outcome in the art of medicine has relied on a balance of previous To BIS or not to BIS? observation (Randomized Controlled Trials) and physiological theory (basic science). Determining the relevance of the B-Aware data to your next patient requires an understanding of the basic science of the problem and the intervention. First, is the risk of awareness in your patient due to similar mechanisms to those in the B-Aware trial? Second, will the BIS (or similar monitor) give equivalent outputs in your patient as the BIS did in the subjects following the B-Aware trial protocol? Last, does the likely benefit to your patient still outweigh any risk or cost?
Our understanding of the basic science of awareness, consciousness, memory, the EEG and mechanisms of anaesthesia is increasing, along with an appreciation of the considerable complexity of how these relate to each other. There is a relationship between EEG and consciousness, but it is inconsistent and variable. No matter how much we fiddle with the EEG, it will never be able to completely predict conscious state in all circumstances. Similarly, it is uncertain that we can yet use basic principles to reliably assess the utility of the processed EEG. Trying to predict the utility of proprietary EEG technologies, from a basic science perspective, is even further hindered by the unknown nature of the algorithms.
In spite of the gaps in basic knowledge, an abundance of limited physiological studies have attempted to assess the performance of proprietary processed EEG technologies in various different populations and circumstances. Using questionable surrogate outcomes, it has been concluded that these technologies often have similar performances in different populations, but sometimes they don't (for example in very small children) 7 .
Eventually we will know much more about the basic science of preventing awareness. Until then, practice using these proprietary products should be governed by the findings of quality randomized controlled trials. The B-Aware trial convincingly demonstrates that adhering to their BIS-guided protocol in high risk groups will significantly reduce the risk of awareness, without prolonging recovery times. What about the next low risk patient on your list? At this stage you should feel neither hindered from using the BIS if you wish to, nor forced to use it if you wish not to.
